Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|February 11, 2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trialMatthew Smith, Chris Parker, Fred Saad, et al.
JCO Precision Oncology|June 21, 2024
Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate CancerDaniel Ang, Johan Chan, Whee Sze Ong, et al.
Asia-Pacific Journal of Clinical Oncology|October 14, 2020
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 studyTie Zhou, Fangjian Zhou, Jianming Guo, et al.
Lung Cancer (Amsterdam, Netherlands)|March 2, 2025
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancerStephanie P L Saw, Angela Takano, Siqin Zhou, et al.
Nature Communications|May 15, 2023
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinomaDarren Wan-Teck Lim, Hsiang-Fong Kao, Lisda Suteja, et al.
JAMA Network Open|November 5, 2021
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung CancerStephanie P L Saw, Siqin Zhou, Jianbin Chen, et al.
Cancer Research|April 8, 2024
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced MutationsChen-Yang Huang, Nanhai Jiang, Meixin Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2022
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancerStephanie P L Saw, Win Pin Ng, Siqin Zhou, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2024
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLCStephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, et al.
JCO Precision Oncology|October 14, 2022
Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung CancerAaron C Tan, Stephanie P L Saw, Jianbin Chen, et al.
Pageof 7